What is Raymond James’ Forecast for TSE:MDP FY2029 Earnings?

Medexus Pharmaceuticals Inc. (TSE:MDP) – Stock analysts at Raymond James issued their FY2029 earnings estimates for Medexus Pharmaceuticals in a research note issued to investors on Tuesday, November 19th. Raymond James analyst R. Sarugaser forecasts that the company will post earnings of $0.89 per share for the year. Raymond James currently has a “Outperform” rating and a $4.00 target price on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

Several other analysts also recently commented on MDP. Leede Financial set a C$8.25 target price on shares of Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a report on Monday, September 30th. Stifel Canada upgraded Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Monday, August 12th. Finally, Stifel Nicolaus increased their price objective on Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Medexus Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of C$5.25.

Medexus Pharmaceuticals Price Performance

Shares of MDP opened at C$2.13 on Thursday. Medexus Pharmaceuticals has a one year low of C$1.44 and a one year high of C$3.16. The company has a market cap of C$52.25 million, a PE ratio of 43.20 and a beta of 1.96. The firm has a 50-day moving average of C$2.47 and a 200-day moving average of C$2.19.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.